JINYU(SH:600201) Zheng Quan Ri Bao Wang·2026-01-07 09:19Core Viewpoint - The major shareholder of Jinyu Biotechnology Co., Ltd. has initiated a share buyback, reflecting confidence in the company's prospects for its African swine fever vaccine development [1][3]. Group 1: Shareholder Actions - As of January 6, 2026, the major shareholder, Inner Mongolia Jinyu Biological Holdings Co., Ltd., has completed its first share buyback, acquiring 614,600 A-shares, which represents 0.0553% of the total share capital, with a total transaction amount of approximately 9.83 million yuan [1]. - The buyback plan was announced on December 24, 2025, with a commitment to purchase shares worth between 50 million and 100 million yuan over the next 12 months [1]. Group 2: Vaccine Development - The urgency for vaccine development is underscored by the ongoing severe African swine fever epidemic, with over 8,000 reported cases globally from January to September 2025 and more than 2 million livestock deaths since 2022 [2]. - The company is collaborating with the Chinese Academy of Sciences to develop a subunit vaccine for African swine fever, which is expected to provide critical technical support for epidemic control and significantly reduce losses in the breeding sector [2]. Group 3: Research and Production Capabilities - The company has established a biosafety level 3 laboratory to support key research activities, including antigen screening and efficacy validation for the vaccine [3]. - The vaccine has received clinical trial approval from the Ministry of Agriculture and Rural Affairs, with the first clinical trial phase completed and the efficacy evaluation stage currently underway [3]. - The company has prepared a GMP-compliant production facility for the vaccine, ensuring readiness for industrialization and quality control [3]. Group 4: Financial Performance - The company has maintained over 10% of its revenue for R&D investment over the past six years, indicating a strong commitment to innovation [4]. - For the first three quarters of 2025, the company reported revenues of 1.042 billion yuan, a year-on-year increase of 7.38%, with a significant profit growth of 116.40% in the third quarter [4].